Figure 2. IU1 treatment accelerates degradation of PrP^C in N2a58 cells.

(a) N2a58 cells were treated with 50 μg/ml CHX combined with various concentrations of IU1 (1–100 μM) for 6 h. Lysates were analyzed by immunoblotting with anti-PrP (SAF32) and anti-β-actin antibodies. (b) N2a58 cells were treated with DMSO, 50 μg/ml CHX alone, or a combination of CHX and 100 μM IU1 for 6 h. Lysates were analyzed by immunoblotting with anti-PrP (SAF32) and anti-β-actin antibodies. (c) Quantification of PrP^C from at least three independent experiments was performed as described in (b). Asterisk indicates significant difference (*P < 0.05). Mean ± SD. (d) HpL cells were transfected with pcDNA3.1 mouse PrP expression plasmid. After 48 h, cells were treated with DMSO, 50 μg/ml CHX alone, or a combination of CHX and 100 μM IU1 for 6 h. Lysates were analyzed by immunoblotting with anti-PrP (SAF83) and anti-β-actin antibodies. (e) N2a58 cells were treated with DMSO, 50 μg/ml CHX alone, or a combination of CHX and 100 μM IU1 for 6 h. PrP^C (SAF32; green) and nuclei (blue) were visualized. Bars: 20 μm.